Neuronal lipid raft perturbations as key elements of early neurodegeneration: A challenge in the search of new tools for early diagnosis

Lipid Rafts: Properties, Controversies and Roles in Signal Transduction

Volumn , Issue , 2014, Pages 219-245

  Marin, Raquel ^a   Diaz, Mario ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Alzheimer's disease; Cerebrospinal fluid biomarkers; Lipid rafts; Parkinson?s disease; Signalosomes

Indexed keywords

EID: 84954585888     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (124)

1. Allen, J. A., Halverson-Tamboli, R. A. & Rasenick, M. M. (2007). Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci., 8(2), 128-40
2. Rushworth, J. V. & Hooper, N. M. (2010). Lipid rafts: Linking Alzheimer?s amyloid-b production, aggregation and toxicity at neuronal membranes. Int J Alzheimer s Dis., 2011, 603052-603064
3. Tsui-Pierchala, B. A., Encinas, M., Milbrandt, J. & Johnson, E. MJr. (2002). Lipid rafts in neuronal signaling and function. Trends Neurosci., 25, 412-417
4. Guirland, C. & Zheng, J. Q. (2007). Membrane lipid rafts and their role in axon guidance. Adv Exp Med Biol., 621, 144-55
5. Michel, V. & Bakovic, M. (2007). Lipid rafts in health and disease. Biol. Cell, 99, 129-140
6. Schengrund, C. L. (2010). Lipid rafts: keys to neurodegeneration. Brain Res Bull., 82(1-2), 7-17
7. Ma, D. W. (2007). Lipid mediators in membrane rafts are important determinants of human health and disease. Appl Physiol Nutr Metab., 32(3), 341-50
8. Gellermann, G. P., Appel, T. R., Tannert, A., Radestock, A., Hortschansky, P., Schroeckh, V., Leisner, C., Lütkepohl, T., Shtrasburg, S., Röcken, C., Pras, M., Linke, R. P., Diekmann, S. & Fändrich, M. (2005). Raft lipids as common components of human extracellular amyloid fibrils. Proc Natl Acad Sci, 102, 6297-6302
9. Kubo, S., Nemani, V. M., Chalkley, R. J., Anthony, M. D., Hattori, N., Mizuno, Y., Edwards, R. H. & Fortin, D. L. (2005). A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem., 280(36), 31664-72
10. Marin, R. (2011). Signalosomes in the brain: relevance in the development of certain neuropathologies such as Alzheimer?s disease. Front Physiol., 2(23), 1-3
11. Hicks, D. A., Nalivaeva, N. N. & Turner, A. (2012). Lipid rafts and Alzheimer?s disease: protein-lipid interactions and perturbation of signaling. Front. Physiol., 3(189), 1-18
12. Duyckaerts, C. & Dickson, D. W. (2003). Neuropathology of Alzheimer's disease, D.W. Dickson (Ed.), Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, ISN Neuropath Press, Basel 47-65
13. Lowe, J., Mirra, S. S., Hyman, B. & Dickson, D. W. (2008). Ageing and Dementia, S. Love, D.N. Louis, D.W. Ellison (Eds.), Greenfield's Neuropathology, Hodder Arnold, London., 1, 1031-1152
14. Abad Rodriguez, J., Ledesma, M. D., Craessaerts, K., Perga, S., Medina, M., Delacourte, A., Dingwall, C., De Strooper, B. & Dotti, C. G. (2004). Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol., 167, 953-960
15. Allinson, T. M. J., Parkin, E. T., Turner, A. J. & Hooper, N. M. (2003). ADAMs family members as amyloid precursor protein a-secretases Journal of Neuroscience Research, vol. 74, no. 3, 342-352
16. Schneider, A., Rajendran, L., Honsho, M., Gralle, M., Donnert, G., Wouters, F., Hell, S. W. & Simons, M. (2008). Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. J Neurosci., 28(11), 2874-82
17. Chen, T. Y., Liu, P. H., Ruan, C. T., Chiu, L. & Kung, F. L. (2006). The intracellular domain of amyloid precursor protein interacts with flotillin- 1, a lipid raft protein. Biochem Biophys Res Commun., 342(1), 266-72
18. Ehehalt, R., Keller, P., Haass, C., Thiele, C. & Simons, K. (2003). Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol., 160, 113-123
19. Kalvodova, L., Kahya, N., Schwille, P., Ehehalt, R., Verkade, P., Drechsel, D. & Simons, K. (2005). Lipids as modulators of proteolytic activity of BACE, involvement of cholesterol, glycosphingolipids & anionic phospholipids in vitro. J Biol Chem, 280, 36815-36823
20. Vetrivel, K. S. & Thinakaran, G. (2010). Membrane rafts in Alzheimer's disease beta-amyloid production. Biochim Biophys Acta., 1801(8), 860-867
21. Kapoor, A., Hsud, W. M., Wang, B. J., Wu, G. H., Lin, T. Y., Lee, S., Yen, Ch. T. & Liayo Y. F. (2010). Caveolin1 regulates secretase mediated AßPP processing by modulating spatial distribution of secretase in membrane. J Alzheimer's Dis., 22, 423-442
22. Harris, B., Pereira, I. & Parkin, E. (2009). Targeting ADAM10 to lipid rafts in neuroblastoma SH-SY5Y cells impairs amyloidogenic processing of the amyloid precursor protein. Brain Res., 1296, 203-15
23. Sakurai, T., Kaneko, K., Okuno, M., Wada, K., Kashiyama, T., Shimizu, H., Akagi, T., Hashikawa, T. & Nukina, N. (2008). Membrane microdomain switching: a regulatory mechanism of amyloidprecursor protein processing. J Cell Biol., 183(2), 339-52
24. Askarova, S., Yang, X. & Lee, J. C. (2011). Impacts of membrane biophysics in Alzheimer's disease: from amyloid precursor protein processing to Aß Peptide-induced membrane changes. Int J Alzheimers Dis. doi, 10.4061/2011/134971.
25. Diaz, M., Fabelo, N. & Marin, R. (2012). Genotype-induced changes in biophysical properties of frontal cortex lipid raft from APP/PS1 transgenic mice. Front. Physiol., 3(3), 1-10
26. Williams, T. L. & Serpell, L. C. (2011). Membrane and surface interactions of Alzheimer's Aß peptide-insights into the mechanism of cytotoxicity. FEBS J., 278(20), 3905-17
27. Kakio, A., Nishimoto, S., Kozutsumi, Y. & Matsuzaki, K. (2003). Formation of a membrane-active form of amyloid beta-protein in raftlike model membranes. Biochem Biophys Res Commun., 303(2), 514-8
28. Hayashi, H., Kimura, N., Yamaguchi, H., Hasegawa, K., Yokoseki, T., Shibata, M., Yamamoto, N., Michikawa, M., Yoshikawa, Y., Terao, K., Matsuzaki, K., Lemere, C. A., Selkoe, D. J., Naiki, H. & Yanagisawa, K. (2004). A seed for Alzheimer amyloid in the brain. J Neurosci., 24(20), 4894-90
29. Bucciantini, M., Nosi, D., Forzan, M., Russo, E., Calamai, M., Pieri, L., Formigli, L., Quercioli, F., Soria, S., Pavone, F., Savistchenko, J., Melki, R. & Stefani, M. (2012). Toxic effects of amyloid fibrils on cell membranes: the importance of ganglioside GM1. FASEB J., 26(2), 818-31
30. Peters, I., Igbavboa, U., Schütt, T., Haidari, S., Hartig, U., Rosello, X., Böttner, S., Copanaki, E., Deller, T., Kögel, D., Wood, W. G., Müller, W. E. & Eckert, G. P. (2009). The interaction of beta-amyloid protein with cellular membranes stimulates its own production. Biochim Biophys Acta, 1788(5), 964-72
31. Malchiodi-Albedi, F., Contrusciere, V., Raggi, C., Fecchi, K., Rainaldi, G., Paradisi, S., Matteucci, A., Santini, M. T., Sargiacomo, M., Frank, C., Gaudiano, M. C. & Diociaiuti, M. (2010). Lipid raft disruption protects mature neurons against amyloid oligomer toxicity. Biochimica Biophysica Acta, 1802(4), 406-415
32. Grimm, M. O., Rothhaar, T. L. & Hartmann, T. (2012). The role of APP proteolytic processing in lipid metabolism. Exp Brain Res., 217(3-4), 365-75
33. Molander-Melin, M., Blennow, K., Bogdanovic, N., Dellheden, B., Månsson, J. E. & Fredman, P. (2005). Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem., 92(1), 171-82
34. Ariga, T., McDonald, M. P. & Yu, R. K. (2008). Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease-a review. J Lipid Res., 49(6), 1157-75
35. Chan, R. B., Oliveira, T. G., Cortes, E. P., Honig, L. S., Duff, K. E., Small, S. A., Wenk, M. R., Shui, G. & Di Paolo, G. (2012). Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem., 287(4), 2678-88
36. Soreghan, B., Thomas, S. N. & Yang, A. J. (2003). Aberrant sphingomyelin/ ceramide metabolic-induced neuronal endosomal/ lysosomal dysfunction: potential pathological consequences in agerelated neurodegeneration. Adv Drug Deliv Rev., 55, 1515-1524
37. Tong, M. & de la Monte, S. M. (2009). Mechanisms of ceramidemediated neurodegeneration. J Alzheimers Dis., 16(4), 705-14
38. Jana, A., Hogan, E. L. & Pahan, K. (2009). Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death. J Neurol Sci., 278(1-2), 5-15
39. Yang, X., Askarova, S. & Lee, J. C. (2010). Membrane biophysics and mechanics in Alzheimer's disease. Mol Neurobiol., 41(2-3), 138-48
40. Wood, W. G., Schroeder, F., Igbavboa, U., Avdulov, N. A. & Chochina, S. V. (2002). Brain membrane cholesterol domains, aging and amyloid beta-peptides. Neurobiol. Aging., 23(5), 685-694
41. Grösgen, S., Grimm, M. O., Friess, P. & Hartmann, T. (2010). Role of amyloid beta in lipid homeostasis. Biochim Biophys Acta., 1801(8), 966-74
42. Simons, M., Keller, P., Dichgans, J. & Schulz, J. B. (2001). Cholesterol and Alzheimer?s disease: is there a link? Neurology, 57, 1089-1093
43. Kojro, E., Gimpl, G., Lammich, S., Marz, W. & Fahrenholz, F. (2001). Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the a-secretase ADAM 10. Proc Natl Acad Sci USA., 98, 5815-5820
44. Cecchi, C., Nichino, D., Zampagni, M., Bernacchioni, C., Evangelisti, E., Pensalfini, A., Liguri, G., Gliozzi, A., Stefani, M. & Relini, A. (2009). A protective role for lipid raft cholesterol against amyloidinduced membrane damage in human neuroblastoma cells. Biochim Biophys Acta, 1788, 2204-2216
45. Kolsch, H., Heun, R., Jessen, F., Popp, J., Hentschel, F., Maier, W. & Lutjohann, D. (2010). Alterations of cholesterol precursor levels in Alzheimer?s disease. Biochim. Biophys. Acta, 1801, 945-950
46. Martin, V., Fabelo, N., Santpere, G., Puig, B., Marín, R., Ferrer, I. & Díaz, M. (2010). Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J Alzheimer's Dis., 19(2), 489-502
47. Young, G. & Conquer, J. (2005). Omega-3 fatty acids and neurophsychiatric disorders. Reprod Nutr Dev, 45(1), 1-28
48. Wassall, S. R. & Stillwell, W. (2009). Polyunsaturated fatty acid cholesterol interactions: domain formation in membranes. Biochim Biophys Acta., 1788(1), 24-32
49. Soderberg, M., Edlund, C., Kristensson, K. & Dallner, G. (1991). Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids, 26, 421-425
50. Plourde, M. & Cunnane, S. C. (2007). Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. Appl Physiol Nutr Metab., 32, 619-634
51. Fabelo, N., Martín, V., Marin, R., Santpere, G., Aso, E., Ferrer, I. & Diaz, M. (2012). Evidence for premature lipid raft aging in APP/PS1 double-transgenic mice, a model of familial Alzheimer disease. J Neuropathol Exp Neurol., 71(10), 868-81
52. Goedert, M. (2001). Alpha-synuclein and neurodegenerative diseases. (2001) Nat Rev Neurosci., 2(7), 492-501
53. Iwatsubo, T. (2003). Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease. J Neurol., 250 (3), 1-4
54. Julien, C., Berthiaume, L., Hadj-Tahar, A., Rajput, A. H., Bédard, P. J., Di Paolo, T., Julien, P. & Calon, F. (2006). Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem Int., 48(5), 404-14
55. Bousquet, M., Calon, F. Cicchetti, F. (2011). Impact of ?-3 fatty acids in Parkinson's disease. Ageing Res Rev., 10(4), 453-63
56. Dalfó, E., Portero-Otín, M., Ayala, V., Martínez, A., Pamplona, R. & Ferrer, I. (2005). Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol., 64(9), 816-30
57. Fabelo, N., Martín, V., Santpere, G., Marin, R., Torrent, L., Ferrer, I. & Díaz, M. (2011). Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. Mol Med., 17(9-10), 1107-18
58. Davidson, W. S., Jonas, A., Clayton, D. F. & George, J. M. (1998). Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem., 273(16), 9443-50
59. Martinez, Z., Zhu, M., Han, S. & Fink, A. L. (2007). GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry, 46(7), 1868-77
60. Cole, N. B., Murphy, D. D., Grider, T., Rueter, S., Brasaemle, D. & Nussbaum, R. L. (2002). Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J Biol Chem., 277(8), 6344-52
61. Yakunin, E., Moser, A., Loeb, V., Saada, A., Faust, P., Crane, D. I., Baes, M. & Sharon, R. (2010). Alpha-Synuclein abnormalities in mouse models of peroxisome biogenesis disorders. J Neurosci Res., 88(4), 866-76
62. Perrin, R. J., Woods, W. S., Clayton, D. F. & George, J. M. (2001). Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J Biol Chem., 276(45), 41958-62
63. Assayag, K., Yakunin, E., Loeb, V., Selkoe, D. J. & Sharon, R. (2007). Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells. Am J Pathol., 171(6), 2000-11
64. Sharon, R., Bar-Joseph, I., Frosch, M. P., Walsh, D. M., Hamilton, J. A. & Selkoe, D. J. (2003). Altered fatty acid composition of dopaminergic neurons expressing a-synuclein and human brains with asynucleinopathies. Neuron, 37, 583-595
65. Barceló-Coblijn, G., Golovko, M. Y., Weinhofer, I., Berger, J. & Murphy, E. J. (2007). Brain neutral lipids mass is increased in alphasynuclein gene-ablated mice. J Neurochem., 101(1), 132-41
66. Lisanti, M. P., Scherer, P. E., Tang, Z. & Sargiacomo, M. (1994). Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis. Trends Cell Biol., 4, 231-235
67. Marino, M., Ascenzi, P. & Acconcia, F. (2006). S-palmitoylation modulates estrogen receptor alpha localization and functions. Steroids, 71, 298-303
68. Pedram, A., Razandi, M., Sainson, R. C., Kim, J. K., Hughes, C. C. & Levin, E. R. (2007). A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem., 282, 22278-22288
69. Murakami, Y., Siripanyapinyo, U., Hong, Y., Kang, J. Y., Ishihara, S., Nakakuma, H., Yusuke, M. & Kinoshita, T. (2003). PIG-W Is Critical for Inositol Acylation but Not for Flipping of Glycosylphosphatidylinositol-Anchor. Mol Biol Cell., 14, 4285-4295
70. Sato, I., Obata, Y., Kasahara, K., Nakayama, Y., Fukumoto, Y., Yamasaki, T., Yokohama, K. K., Saito, T. & Yamaguchi, N. (2009). Differential trafficking of Src, Lyn, Yes and Fyn is specified by the state of palmitoylation in the SH4 domain, J Cell Sci., 122(Pt 7), 965-975
71. Morrow, I. C., Rea, S., Martin, S., Prior, I. A., Prohaska, B., Hancock, J. F., James, D. E. & Parton, R. G. (2002). Flotillin-1/Reggie-2 traffics to surface raft domains via a novel Golgi-independent pathway. J Biol Chem., 277, 48834-48841
72. Meitzen, J., Luoma, J. I., Boulware, M. I., Hedges, V. L., Peterso, B. M., Tuomela, K., Britson, K. A. & Mermelstein, P. G. (2013). Palmitoylation of estrogen receptors is essential for neuronal membrane signaling. Endocrinology, doi, 10.1210/en.2013-1172
73. Lingwood, D. & Simons, K. (2010). Lipid rafts as a membrane organizing principle. Science, 327, 46-50
74. Parton, R. G. (2003). Caveolae-form ultrastructure to molecular mechanisms. Nat. Rev. Mol. Cell Biol., 4, 162-167
75. Lajoie, P., Goetz, J. G., Dennis, J. W. & Nabi, I. R. (2009). Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane. J. Cell Biol., 185, 381-385
76. Kapoor, A., Hsud, W. M., Wang, B. J., Wu, G. H., Lin, T. Y., Lee, S., Yen, ChT. & Liao, Y. F. (2010). Caveolin1 regulates secretase mediated AbPP processing by modulating spatial distribution of secretase in membrane. J. Alzheimer's Dis., 22, 423-442
77. Marin, R., Ramirez, C. M., Morales, A., Gonzalez, M., Alonso, R. & Diaz, M. (2008). Modulation of Ab-induced neurotoxicity by estrogen receptor alpha and other associated proteins in lipid rafts. Steroids, 73, 992-996
78. Madeira, A., Yang, J., Zhang, X., Vikeved, E., Nilsson, A., Andrén, P. E. & Svenningsson, P. (2011). Caveolin-1 interacts with alpha-synuclein and mediates toxic actions of cellular alpha-synuclein overexpression. Neurochem Int., 59(2), 280-9
79. Swanwick, C. C., Shapiro, M. E., Yi, Z., Chang, K. & Wenthold, R. J. (2009). NMDA receptors interact with flotillin-1 and -2, lipid raftassociated proteins. FEBS Lett., 583(8), 1226-30
80. Swanwick, C. C., Shapiro, M. E., Vicini, S. & Wenthold, R. J. (2010). Flotillin-1 promotes formation of glutamatergic synapses in hippocampal neurons. Dev Neurobiol, 70(13), 875-83
81. Williamson, R., Usardi, A., Hanger, D. P. & Anderton, B. H. (2008). Membrane-bound beta-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism. FASEB J., 22(5), 1552-9
82. Minami, S. S., Hoe, H. S. & Rebeck, G. W. (2011). Fyn kinase regulates the association between amyloid precursor protein and Dab1 by promoting their localization to detergent-resistant membranes. J Neurochem., 118(5), 879-90
83. Won, J. S., Im, Y. B., Kim, J., Singh, A. K. & Singh, I. (2010). Involvement of AMP-activated-protein-kinase (AMPK) in neuronal amyloidogenesis. Biochem Biophys Res Commun., 399(4), 487-91
84. Marin, R., Diaz, M., Alonso, R., Sanz, A., Arevalo, M. A. & Garcia- Segura, L. M. (2009). Role of estrogen receptor in membrana-initiated signaling in neural cells: interaction with IGF-1 receptor. J. Steroid Biochem. Mol. Biol., 114, 2-7
85. Marin, R., Ramírez, C. M., González, M., González-Muñoz, E., Zorzano, A., Camps, M., Alonso, R. & Díaz, M. (2007). Voltagedependent anion channel (VDAC) participates in amyloid beta-induced toxicity and interacts with plasma membrane estrogen receptor a in septal and hippocampal neurons. Mol. Memb. Biol., 24, 148-60
86. Herrera, J. L., Diaz, M., Hernández-Fernaud, J. R., Salido, E., Alonso, R., Fernández, C., Morales, A. & Marin, R. (2011). Voltage-dependent anion channel as a resident protein of lipid rafts: post-transductional regulation by estrogens and involvement in neuronal preservation against Alzheimer's disease. J Neurochem., 116(5), 820-7
87. Micevych, P. & Christensen, A. (2012). Membrane-initiated estradiol actions mediate structural plasticity and reproduction. Front Neuroendocrinol., 33(4), 331-41
88. Hashimoto, M., Takenouchi, T., Rockenstein, E. & Masliah, E. (2003). Alpha-synuclein up-regulates expression of caveolin-1 and downregulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson?s disease. J. Neurochem., 85, 14681-1479
89. Benarroch, E. E. (2007). Lipid rafts, protein scaffolds, and neurologic disease. Neurology, 69, 1635-1639
90. Sidhu, A., Wersinger, C. & Vernier, P. (2004). Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J., 18, 637-647
91. Fortin, D. L., Troyer, M. D., Nakamura, K., Kubo, S., Anthony, M. D. & Edwards, R. H. (2004). Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci., 24, 6715-6723
92. Ihara, M., Yamasaki, N., Hagiwara, A., Tanigaki, A., Kitano, A., Hikawa, R., Tomimoto, H., Noda, M., Takanashi, M., Mori, H., Hattori, N., Miyakawa, T. & Kinoshita, M. (2007). Setp4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron, 53, 519-533
93. Chadwick, W., Brenneman, R., Martin, B. & Maudsley, S. (2010). Complex and multidimensional lipid raft alterations in a murine model of Alzheimer?s disease. Int J Alzheimers Dis., 2010, 604-792
94. Han, X., Rozen, S., Boyle, S. H., Hellegers, C., Cheng, H., Burke, J. R., Welsh-Bohmer, K. A., Doraiswamy, P. M. & Kaddurah-Daouk, R. (2011). Metabolomics in early Alzheimer?s disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS ONE, 6, e21643. doi, 10.1371/journal.pone.0021643
95. Han, X., Holtzman, D. M., McKeel, D. W., Kelley, J. & Morris, J. C. (2002). Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer?s disease: potential role in disease pathogenesis. Journal of Neurochemistry, 82(4), 809-818
96. Gottfries, C. G, Karlsson, I. & Svennerholm, L. (1996). Membrane components separate early-onset Alzheimer's disease from senile dementia of the Alzheimer type. Int Psychogeriatr., 8(3), 365-72
97. Janvin, C. C., Larsen, J. P., Aasrland, D. & Hugdahl, K. (2006). Subtypes of mild cognitive impairment in Parkinson?s disease: progression to dementia. Mov Disord., 21(9), 1343-9
98. Poletti, M., Emre, M. & Bonuccelli, U. (2011). Mild cognitive impairment and cognitive reserve in Parkinson?s disease. Parkinsonism Relat Disord., 17(8), 579-86
99. Markesbery, W. R., Kryscio, R. J., Lovell, M. A. & Morrow, J. D. (2005). Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol., 58(5), 730-735
100. Montine, T. J. & Morrow, J. D. (2005). Fatty acid oxidation in the pathogenesis of Alzheimer?s disease. American Journal of Pathology, 166(5), 1283-1289
101. Tsang, A. H. & Chung, K. K. (2009). Oxidative and nitrosative stress in Parkinson's disease. Biochim Biophys Acta., 1792(7), 643-50
102. Braak, H. & Braak, E. (1991). Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol, 82, 239-259
103. Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A. & Tanner, C. M. (2007). Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 68, 384-386
104. Dubois, B., Feldman, H. H., Jacova, C., Dekosky, S. T., Barberger- Gateau, P., Cummings, J., et al. (2007). Research criteria for the diagnosis of Alzheimer?s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol, 6(8), 734-746
105. Forlenza, O. V., Diniz, B. S. & Gattaz, W. F. (2010). Diagnosis and biomarkers of predementia in Alzheimer?s disease. BMC Med, 8, 89-94
106. Rosén, C., Hansson, O., Blennow, K. & Zetterberg, H. (2013). Fluid biomarkers in Alzheimer's disease-current concepts. Mol Neurodegener., 8, 20-31
107. Busse, A., Bischkopf, J., Riedel-Heller, S. G. & Angermeyer, M. C. (2003). Mild cognitive impairment: prevalence and predictive validity according to current approaches. Acta Neurol Scand, 108(2), 71-81
108. Bennett, D. A., Wilson, R. S., Schneider, J. A., Evans, D. A., Beckett, L. A., Aggarwal, N. T., Barnes, L. L., Fox, J. H. & Bach, J. (2002). Natural history of mild cognitive impairment in older persons. Neurology, 59, 198-205
109. Petersen, R. C. (2003). Mild cognitive impairment: aging to Alzheimer?s disease. Oxford; New York: Oxford University Press
110. Breen, D. P., Michell, A. W. Barker, R. A. (2011). Parkinson?s disease -the continuing search for biomarkers. Clin Chem Lab Med, 49, 393-401
111. Ross, G. W., Abbott, R. D., Petrovitch, H., Tanner, C. M., Davis, D. G., Nelson, J., Markesbery, W. R., Hardman, J., Masaki, K., Launer, L. & White, L. R. (2006). Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord., 21(12), 2062-7
112. Lerner, A. & Bagic, A. (2008). Olfactory pathogenesis of idiopathic Parkinson disease revisited. Mov Disord., 23(8), 1076-84
113. Del Tredici, K., Rüb, U., De Vos, R. A., Bohl, J. R. & Braak, H. (2002). Where does parkinson disease pathology begin in the brain? J Neuropathol Experiment Neurol., 61(5), 413-26
114. Kang, J. H., Irwin, D. J., Chen-Plotkin, A. S., Siderowf, A., Caspell, C., Coffey, C. S., Waligórska, T., Taylor, P., Pan, S., Frasier, M., Marek, K., Kieburtz, K., Jennings, D., Simuni, T., Tanner, C. M., Singleton, A., Toga, A. W., Chowdhury, S., Mollenhauer, B., Trojanowski, J. Q., Shaw, L. M. the Parkinson?s Progression Markers Initiative. (2013). Association of Cerebrospinal Fluid ß-Amyloid 1-42, T-tau, P-tau181, and a-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. JAMA Neurol., doi, 10.1001/ jamaneurol.2013.3861
115. van Dijk, K. D., Teunissen, C. E., Drukarch, B., Jimenez, C. R., Groenewegen, H. J., Berendse, H. W. & van de Berg, W. D. (2010). Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease, a pathogenetically based approach. Neurobiol Dis., 39(3), 229-41
116. Wilhelmus, M. M. M. (2011). Apolipoprotein and LRP1 increase early in Parkinson's disease pathogenesis. Am J Pathol, 179(5), 2152-2156
117. Marin, R., Rojo, J. A., Fabelo, N., Fernandez, C. E. & Diaz, M. (2013). Lipid raft disarrangement as a result of neuropathological progresses: a novel strategy for early diagnosis? Neuroscience., 245, 26-39
118. Hur, J. Y., Teranishi, Y., Kihara, T., Yamamoto, N. G., Inoue, M., Hosia, W., Hashimoto, M., Winblad, B., Frykman, S. & Tjernberg, L. O. (2012). Identification of novel ?-secretase-associated proteins in detergent-resistant membranes from brain. J Biol Chem., 287(15), 11991-2005
119. Galasko, D. & Montine, T. J. (2010). Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med., 4(1), 27-36
120. Uehara, T., Nakamura, T., Yao, D., Shi, Z. Q., Gu, Z., Ma, Y., Masliah, E., Nomura, Y. & Lipton, S. A. (2006). S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature, 441(7092), 513-7
121. Cho, D. H., Nakamura, T., Fang, J., Cieplak, P., Godzik, A., Gu, Z. & Lipton, S. A. (2009). S-nitrosylation of Drp1 mediates beta-amyloidrelated mitochondrial fission and neuronal injury. Science, 324(5923)., 102-5
122. Kwak, Y. D., Wang, R., Li, J. J., Zhang, Y. W., Xu, H. & Liao, F. F. (2010). Differential regulation of BACE1 expression by oxidative and nitrosative signals. Mol Neurodegener., 6, 17-25
123. Ortega, F., Stott, F. J., Visser, S. A. & Bendtsen, C. (2013). Interplay between alpha-, beta-, and gamma-secretases determines biphasic amyloid-beta protein level in the presence of a gamma-secretase inhibitor. J Biol Chem., 288, 785-792
124. Swomley, A. M., Förster, S., Keeney, J. T., Triplett. J., Zhang. Z., Sultana, R. & Butterfield, D. A. (2013). Abeta, oxidative stress in Alzheimer disease: Evidence based on proteomics studies. Biochim Biophys Acta., S0925-4439(13)00297-4